Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07776054 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.
Trial Details
NCT Number NCT07776054
Lead Sponsor Samsung Medical Center
Conditions
(from sponsor)		 Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion
Related terms Atrial Fibrillation
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov